



ASX ANNOUNCEMENT

15 JANUARY 2024

ADVENT-AML PHASE 1B CLINICAL TRIAL OPEN TO ENROLMENT

- ADVENT-AML (CHM 0201 + Azacitidine + Venetoclax) Phase 1B clinical trial now open to enrollment at The University of Texas MD Anderson Cancer Center
- Enrolment open to patients with relapsed / refractory Acute Myeloid Leukemia (AML), before the trial recruits up to 20 patients with newly diagnosed AML
- ADVENT-AML trial is the first clinical trial to evaluate NK cells in combination with the current AML standard of care therapy

Sydney, Australia, 15 January 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the Phase 1B ADVENT-AML clinical trial is now open to enrollment at The University of Texas MD Anderson Cancer Center. The ADVENT-AML Phase 1B study is evaluating Chimeric’s off-the-shelf universal donor NK cell therapy CHM 0201 in combination with standard of care therapy for patients with newly diagnosed Acute Myeloid Leukemia (AML).

The ADVENT-AML (NCT05834244) Phase 1B clinical trial is an investigator-initiated study at The University of Texas MD Anderson Cancer Center under Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia.

The study is the first trial to evaluate the synergy of NK cell therapy in combination with the current standard of care, Azacitidine and Venetoclax. The study is designed to enroll up to 20 subjects with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant, following an initial dose confirmation cohort assessing the safety of this novel combination treatment in subjects with relapsed or refractory AML.

“We are very excited that the ADVENT AML clinical trial is now open to enrollment as it marks a first and important milestone in the investigation of NK cells in combination with current AML standard of care therapy,” said Jennifer Chow, CEO and Managing Director of Chimeric Therapeutics. “With the high unmet medical needs in AML and the promising synergy demonstrated with NK cells in combination with Azacitidine and Venetoclax, this trial has potential to significantly enhance outcomes for AML patients.”

Under the terms of the clinical trial agreement with MD Anderson, Chimeric will provide CHM 0201 study drug as well as partial financial support for study. In addition to the modest financial support from Chimeric, the study will be supported by grant funding from multiple funding sources including Gateway for Cancer Research.

For personal use only



ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2023.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase 1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Jennifer Chow

Chief Executive Officer and Managing Director
Chimeric Therapeutics

T: + 1 9087238387

E: jchow@chimerictherapeutics.com

W: www.chimerictherapeutics.com

Paul Hopper

Executive Chairman
Chimeric Therapeutics

T: + 61 406 671 515

E: paulhopper@lifescienceportfolio.com

For personal use only



Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: matt@nwrcommunications.com.au

For personal use only